CatC inhibitor Phase II in non CF bronchiectasis
Research payments
$615,988
Through program year 2023, $615,988 in research payments was reported against CatC inhibitor Phase II in non CF bronchiectasis, across 42 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $458,053 | 22 |
| 2022 | Research | $157,935 | 20 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Charles Andrews San Antonio, TX Named on 8 payments
- Peruvemba Sriram Gainesville, FL Named on 6 payments
- Patrick Flume Charleston, SC Named on 5 payments
- Brian Morrissey Sacramento, CA Named on 5 payments
- Reginald Fowler Hilton Head Island, SC Named on 4 payments
- Andreas Schmid Kansas City, MO Named on 2 payments
- Maria Indihar Cincinnati, OH Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.